Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant.
OBJECTIVE
The authors present the use of synthetic factor VIIa to treat bleeding after cardiopulmonary bypass and surgical repair of an atrial septal defect in an infant with trisomy 10 and pulmonary hypertension.


METHODS
Case report.


METHODS
University-affiliated pediatric intensive care unit.


METHODS
A 4-mo-old, 3.7-kg infant.


RESULTS
After a single dose of synthetic factor VIIa, there was normalization of the prothrombin and partial thromboplastin time and cessation of bleeding.


CONCLUSIONS
The potential benefits of synthetic factor VIIa when compared with conventional therapy with fresh frozen plasma are discussed. Previous experience with synthetic factor VIIa in pediatric-aged patients and the cardiothoracic surgical population is presented.
Tobias
Joseph D
JD
Department of Anesthesiology, University of Missouri, Columbia, MO, USA.
Berkenbosch
John W
JW
Russo
Pierantonio
P
D002315:Cardiopulmonary Bypass; D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006330:Heart Defects, Congenital / Q000601:surgery*; D006344:Heart Septal Defects, Atrial / Q000601:surgery*; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007223:Infant; D010314:Partial Thromboplastin Time; D011517:Prothrombin Time
D015942:Factor VIIa